The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought

Value in Health

Volumn 19, Issue 8, 2016, Pages 921-928

  Wilkinson, Thomas ^a   Sculpher, Mark J ^b   Claxton, Karl ^b   Revill, Paul ^b   Briggs, Andrew ^c   Cairns, John A ^d   Teerawattananon, Yot ^e   Asfaw, Elias ^f   Lopert, Ruth ^g,h   Culyer, Anthony J ^b   Walker, Damian G ⁱ  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF YORK   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e MINISTRY OF PUBLIC HEALTH   (Thailand)

^f UNIVERSITY OF KWAZULU NATAL   (South Africa)

^g GEORGE WASHINGTON UNIVERSITY   (United States)

^h MANAGEMENT SCIENCES FOR HEALTH   (United States)

ⁱ BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMIC EVALUATION; HUMAN; INFORMATION SEEKING; LOW INCOME COUNTRY; MEDICAL DECISION MAKING; MIDDLE INCOME COUNTRY; PRIORITY JOURNAL; STANDARD; WORLD HEALTH ORGANIZATION; CAPACITY BUILDING; COST BENEFIT ANALYSIS; COST OF ILLNESS; DECISION MAKING; DEVELOPING COUNTRY; GLOBAL HEALTH; HEALTH CARE POLICY; PROCEDURES; UNCERTAINTY;

CAPACITY BUILDING; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DECISION MAKING; DEVELOPING COUNTRIES; GLOBAL HEALTH; HEALTH POLICY; HUMANS; UNCERTAINTY;

EID: 85006118711     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2016.04.015     Document Type: Article

References (43)

1. [1] Culyer, A.J., The Dictionary of Health Economics. 3rd ed., 2014, Edward Elgar, Cheltenham, UK.
2. [2] Drummond, M.F., Sculpher, M.J., Claxton, K., et al. Methods for the Economic Evaluation of Health Care Programmes. 4th ed., 2015, Oxford University Press, Oxford, UK.
3. [3] International Decision Support Initiative. The reference case for economic evaluation. 2015. Available from: www.idsihealth.org/knowledge_base/the-reference-case-for-economic-evaluation. [Accessed January 5, 2015].
4. [4] Gold, M.R., Russell, L.B., Siegel, J.E., Weinstein, M.C., Cost-Effectiveness in Health and Medicine. 1996, Oxford University Press, New York, NY.
5. [5] Edejer, T.T.T., Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Vol. 1, 2003, World Health Organization, Geneva, Switzerland.
6. [6] National Institute for Clinical Excellence. Scientific and Social Value Judgements. 2004, National Institute for Clinical Excellence, London.
7. [7] Drummond, M., Barbieri, M., Cook, J., et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health 12 (2009), 409–418.
8. [8] Sculpher, M.J., Pang, F.S., Manca, A., et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess, 8, 2004 iii–iv, 1–192.
9. [9] Murray, C.J., Evans, D.B., Acharya, A., Baltussen, R.M., Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ 9 (2000), 235–251.
10. [10] Eldessouki, R., Smith, M.D., Health care system information sharing: a step toward better health globally. Value Health Reg Issues 1 (2012), 118–129.
11. [11] Gray, A.M., Clarke, P.M., Wolstenholme, J.L., Wordsworth, S., Applied Methods of Cost-Effectiveness Analysis in Health Care. 2010, Oxford University Press, New York, NY.
12. [12] Chalkidou K, Glassman A, Marten R, et al. Priority setting for achieving universal health coverage [published online ahead of print 2016]. Bull World Health Organ. BLT.15.155721.
13. [13] Culyer, A.J., Lomas, J., Deliberative processes and evidence-informed decision-making in health care—do they work and how might we know?. Evid Policy 2 (2006), 357–371.
14. [14] Bill and Melinda Gates Foundation. Available from: http://www.gatesfoundation.org/How-We-Work. [Accessed November 3, 2015].
15. [15] NICE International. Health Intervention and Technology Assessment Program, Thailand, Centre for Health Economics, University of York, Bill and Melinda Gates Foundation. Methods for Economic Evaluation Project (MEEP) Final Report. 2014, National Institute for Health and Care Excellence, London.
16. [16] Santatiwongchai, B., Chantarastapornchit, V., Wilkinson, T., et al. Methodological variation in economic evaluations conducted in low- and middle-income countries: information for reference case development. PLoS One, 10, 2015, e0123853.
17. [17] NICE International. Health Intervention and Technology Assessment Program, Thailand, Centre for Health Economics, University of York, Bill and Melinda Gates Foundation. The Gates Reference Case, What It Is, Why It Is Important, and How to Use It. 2014, National Institute for Health and Care Excellence, London.
18. [18] Van Baal, P., Thongkong, N., Severens, JL., Human resource constraints and the methods of economic evaluation of health care technologies. IDSI Working Group Report, In press November, 2015.
19. [19] Heggie, R., Hawkins, N., Wu, O., dummy Evidence Working Group Report. IDSI Working Group Report, In press November, 2015.
20. [20] Moller, L.C., Ethiopia's Great Run: The Growth Acceleration and How to Pace It. 2015, World Bank Group, Washington, DC.
21. [21] Wang, H., Ramana, G.N.V., Ethiopia—Universal Health Coverage for Inclusive and Sustainable Development: Country Summary Report. 2014, World Bank Group, Washington, DC.
22. [22] Bikilla, A.D., Jerene, D., Robberstad, B., et al. Cost-effectiveness of anti-retroviral therapy at a district hospital in southern Ethiopia. Cost Effectiveness and Resource Allocation 7 (2009), 1–11.
23. [23] Kombe, G, Galaty, D, Gadhia, R & Decker. Human and financial resource requirements for scaling up HIV/AIDS services in Ethiopia. Bethesda, MD: The Partners for Health Reform plus Project, Abt Associates Inc, 2004.
24. [24] Johns, B., Asfaw, E., Wong, W., et al. Assessing the Costs and Effects of Antiretroviral Therapy Task Shifting From Physicians to Other Health Professionals in Ethiopia. Acquir Immune Defic Syndr 65 (2014), 140–147.
25. [25] Asfaw, E., Tushune, K., Abdosh, B., et al. Cost Effectiveness Analysis of PMTCT Service Delivery Modalities in Addis Ababa (Using Decision Models). Social Science Research Network, 2012 Available from: http://ssrn.com/abstract=2180719. [Accessed May 2, 2014.].
26. [26] Bikilla, A.D., Jerene, D., Robberstad, B., et al. Cost estimates of HIV care and treatment with and without anti-retroviral therapy at Arba Minch Hospital in southern Ethiopia. Cost Effectiveness and Resource Allocation 7 (2009), 1–7.
27. [27] FHAPCO. Unpublished. Facility-Based Anti-Retroviral Treatment Costing Study in Ethiopia. 2012, Federal HIV/AIDS Prevention and Control Office, Federal Ministry of Health, Ethiopia Addis Ababa.
28. [28] Afsaw, E., Mbonigaba, J., Kayes, S., et al. Economic evaluation in Ethiopian healthcare sector decision making: Perception, practice and barriers. Applied Health Economics and Health Policy, manuscript submitted on Mar, 2016.
29. [29] Husereau, D., Drummond, M., Petrou, S., et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMC Med, 11, 2013, 80.
30. [30] Karlsson, G., Johannesson, M., The decision rules of cost-effectiveness analysis. Pharmacoeconomics 9 (1996), 113–120.
31. [31] Murray, C.J., Lopez, A.D., Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 349 (1997), 1498–1504.
32. [32] World Health Organization. Choosing Interventions That Are Cost Effective (WHO-CHOICE). 2010, WHO, Geneva, Switzerland.
33. [33] National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal. 2013, National Institute for Health and Care Excellence, London.
34. [34] Pharmaceutical Management Agency of New Zealand. Prescription for Pharmacoeconomic Analysis. 2012, Pharmaceutical Management Agency of New Zealand, Wellington, New Zealand.
35. [35] Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada. 3rd ed., 2006, Canadian Agency for Drugs and Technologies in Health, Ottawa, ON.
36. [36] Thavorncharoensap, M., Measurement of health outcomes. J Med Assoc Thai 97:Suppl. 5 (2014), S27–S32.
37. [37] Anand, S., Hanson, K., Disability-adjusted life years: a critical review. J Health Econ 16 (1997), 685–702.
38. [38] Gold, M.R., Stevenson, D., Fryback, D.G., HALYS and QALYS and DALYS, oh my: similarities and differences in summary measures of population health. Ann Rev Public Health 23 (2002), 115–134.
39. [39] Lipscomb, J., Drummond, M., Fryback, D., et al. Retaining, and enhancing, the QALY. Value Health 12:Suppl. 1 (2009), S18–S26.
40. [40] Claxton, K., Martin, S., Soares, M., et al. Methods for the estimation of the NICE cost effectiveness threshold. Health Technol Assess, 19, 2015, 503.
41. [41] Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. CHE Research Paper 109, Centre for Health Economics, University of York, York, UK, March 3, 2015.
42. [42] International Decision Support Initiative. Determining value from healthcare spending: the role of cost-effectiveness thresholds. 2015. Available from: www.idsihealth.org/knowledge_base/cost-effectiveness-thresholds/. [Accessed August 2, 2015].
43. [43] Chootipongchaivat S et al. Vaccination program in a resource-limited setting: A case study in the Philippines. Vaccine (2016). Available from: http://dx.doi.org/10.1016/j.vaccine.2016.08.014. [Accessed September 1, 2016].